By Brazil Stock Guide – Brazil’s Hypera Pharma (HYPE3.SA) reported a sharp increase in first-quarter earnings and revenue, driven by stronger retail performance, margin expansion and a capital injection that improved its balance sheet.
Hypera said net revenue reached 2.02 billion reais ($—), marking an 86.7% increase from a year earlier, while gross margin rose to 60%, up 1,280 basis points.
Net income from continuing operations totaled 345.7 million reais, while EBITDA reached 586.5 million reais, both showing significant nominal gains compared to the same period last year.
Retail growth outpaces market
The company highlighted a 9.4% increase in pharmaceutical retail sell-out, outperforming market growth in its operating categories by 1.5 percentage points.
Hypera also reported improvements in logistics and distribution metrics, including a 12 percentage-point rise in on-time, in-full deliveries (OTIF) and a 14% increase in order cycle time efficiency.
Capital increase strengthens balance sheet
A key driver of the quarter was a private capital increase that generated 1.5 billion reais in cash inflow.
The company said the move reduced net debt by 18% and helped lower exposure to credit market volatility, while also cutting interest expenses and expanding investment capacity.
Cash flow data shows improved liquidity, with financing inflows offsetting debt obligations and supporting a net leverage ratio of 2.2 times EBITDA.
Cost dynamics and expenses
Marketing expenses declined 8.6% year-over-year to 335.8 million reais, while selling expenses rose 2.7% and general and administrative costs increased 13.9%.
The combination of higher revenue and cost discipline contributed to margin expansion and profitability gains during the quarter.
Leave a Reply